Adipose tissue-derived stem cells ameliorate hyperglycemia, insulin resistance and liver fibrosis in the type 2 diabetic rats

作者：Liao, Naishun; Zheng, Youshi; Xie, Haihua; Zhao, Bixing; Zeng, Yongyi; Liu, Xiaolong^*; Liu, Jingfeng^*

来源：Stem Cell Research & Therapy, 2017, 8(1): 286.

DOI：10.1186/s13287-017-0743-7

• Adipose tissue-derived stem cells
• Type 2 diabetes
• Liver fibrosis
• TGF-beta 1/SMAD3 signaling pathway

Background: Type 2 diabetes (T2D) is closely associated with liver fibrosis, but no effective treatments are currently available. This study was designed to investigate the therapeutic effects of ADSCs on insulin resistance, hyperglycemia, and liver fibrosis on T2D rats.
Methods: We first established a T2D rat model with liver fibrosis by using the combination of a high-fat diet (HFD), low-dose streptozotocin (STZ), and carbon tetrachloride (CCl4). Subsequently, the model rats were administrated by tail vein injection of PBS or ADSCs, respectively. Thereafter, insulin resistance and liver function were assessed by biochemical analysis, ELISA, histopathological examination, and q-PCR assay, respectively. Moreover, the molecular mechanisms of ADSCs on the effect of the TGF-beta 1/SMAD3 signaling pathway were further analyzed.
Results: Our data showed that ADSC transplantation significantly alleviated insulin resistance and hyperglycemia in the liver-injured T2D rats. We also found that ADSC transplantation could attenuate liver injury by improving liver function and inhibiting pathological changes of liver fibrosis, as well as through downregulation of TGF-beta 1 and phosphorylated SMAD3 both in vitro and in vivo.
Conclusions: These findings suggested that ADSC transplantation can ameliorate insulin resistance, hyperglycemia, and liver fibrosis via suppressing TGF-beta 1/SMAD3 signaling, which may provide a potential treatment strategy for liver fibrosis of T2D.

• 出版日期2017-12-19
• 单位福建医科大学